Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers

Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers

Feb 12, 2021
|
Caroline Hopkins
Premium

NEW YORK – In metastatic castration-resistant prostate cancer (mCRPC), the progression-free survival benefit of adding AstraZeneca's investigational VEGF inhibitor cediranib to the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) may be limited to patients with homologous recombination repair (HRR)-deficient cancers, according to a new biomarker analysis presented Thursday during the American Society of Clinical Oncology's Genitourinary Cancers Symposium.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar
30
Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

What's Popular?

In Cancer

  1. UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer

  2. Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

  3. MSK Study Finds Survival Gap Between Clinical Trial, Real-World Patients on Approved Cancer Drugs

    Premium

  4. Genetic Testing Challenges in Oncology: Forged Genetic Test Report Leads to Incorrect Management

  5. McKesson-led Consortium to Establish Best Practices for Lung Cancer Molecular Testing, Treatment

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.